Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. (Q37968620)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22171583%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22171583%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

0 references

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22171583%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Matthias Mehling

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22171583%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

David Leppert

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22171583%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Özgür Yaldizli

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22171583%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Raija L P Lindberg

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22171583%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Jens Kuhle

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22171583%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Ludwig Kappos

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22171583%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

1 January 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22171583%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

number of pages

27

1 reference

inferred from page(s)

published in

CNS Drugs

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22171583%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22171583%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22171583%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

11-37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22171583%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

The epidemiology of multiple sclerosis in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Secondary progressive multiple sclerosis: current knowledge and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Primary-progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Glatiramer acetate treatment in PPMS: why males appear to respond favorably.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Antibody engineering principles and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Hypersensitivity reactions to last generation chimeric, humanized [correction of umanized] and human recombinant monoclonal antibodies for therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Drug insight: using monoclonal antibodies to treat multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Treatment of inflammatory and paraproteinemic neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Treatment of immune-mediated, dysimmune neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Response to rituximab and prednisolone for opsoclonus-myoclonus-ataxia syndrome in a child with ganglioneuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinase-positive myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Rituximab in the management of refractory myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Rituximab for severe myasthenia gravis--experience from five patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

An open label study of the effects of rituximab in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Treatment of stiff person syndrome with rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Rituximab treatment of stiff-person syndrome in a patient with thymoma, diabetes mellitus and autoimmune thyroiditis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Stiff-person syndrome: persistent elevation of glutamic acid decarboxylase antibodies despite successful treatment with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Natalizumab for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

alpha4-Integrin antagonism with natalizumab: effects and adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

A controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

[Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Asymptomatic reactivation of JC virus in patients treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Seroepidemiology of human polyomaviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Prevalence of Antibodies in Human Sera against JC Virus, an Isolate from a Case of Progressive Multifocal Leukoencephalopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Assay design and sample collection can affect anti-John Cunningham virus antibody detection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Primary central nervous system lymphoma in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Biology and treatment of primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Melanoma complicating treatment with natalizumab for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

B-cell targeting in rheumatoid arthritis and other autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

A review of the current use of rituximab in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Rituximab for Immune Cytopenia in Adults: Idiopathic Thrombocytopenic Purpura, Autoimmune Hemolytic Anemia, and Evans Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Treatment of refractory chronic GVHD with rituximab: a GITMO study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

The therapeutic potential of anti-CD20 "what do B-cells do?".

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

The biology of interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Case records of the Massachusetts General Hospital. Case 36-2007. A 31-year-old woman with rash, fever, and hypotension

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

IL-12 unmasks latent autoimmune disease in resistant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

The role of APRIL and BAFF in lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

The role of BAFF in immune function and implications for autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

The complex clinical picture of side effects to biologicals

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Daclizumab in treatment of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Natalizumab effects on immune cell responses in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Rituximab therapy in monoclonal IgM-related neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11596920-000000000-00000

Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease)

21 January 2018

1 reference

12 December 2020

Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines

1 reference

12 December 2020

Successful treatment with rituximab in a patient with stiff-person syndrome complicated by dysthyroid ophthalmopathy

1 reference

12 December 2020

Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients

1 reference

12 December 2020

Effect of Campath-1H antibody on human hematopoietic progenitors in vitro

1 reference

12 December 2020

Primary chronic cold agglutinin disease: a population based clinical study of 86 patients.

1 reference

12 December 2020

Asymptomatic reactivation of JC virus in patients treated with natalizumab

1 reference

12 December 2020

Seroepidemiology of the human polyomaviruses

1 reference

12 December 2020

Interleukin-12: a proinflammatory cytokine with immunoregulatory functions

1 reference

12 December 2020

Rituximab-responsive CIDP

1 reference

12 December 2020

Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 reference

12 December 2020

Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study

1 reference

12 December 2020

Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses

1 reference

12 December 2020

Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome

1 reference

12 December 2020

Anti-alpha4 integrin antibody induces apoptosis in murine thymocytes and staphylococcal enterotoxin B-activated lymph node T cells

1 reference

12 December 2020

Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study

1 reference

12 December 2020

Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis

1 reference

12 December 2020

Characterization of a human B cell-specific antigen (B2) distinct from B1

1 reference

12 December 2020

Monozygotic twins with stiff person syndrome and autoimmune thyroiditis: rituximab inefficacy in a double-blind, randomised, placebo controlled crossover study

1 reference

12 December 2020

Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma?

1 reference

12 December 2020

Natalizumab and central nervous system lymphoma: no clear association

1 reference

12 December 2020

Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human-anti-human IL-12p40 antibody

1 reference

12 December 2020

Development and characterization of mouse hybridomas

1 reference

12 December 2020

Ocular toxoplasmosis during natalizumab treatment

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

[Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment]

1 reference

12 December 2020

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study

1 reference

12 December 2020

A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells

1 reference

12 December 2020

Interleukin 2 receptor (Tac antigen) expression in HTLV-I-associated adult T-cell leukemia.

1 reference

12 December 2020

Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis.

1 reference

12 December 2020

Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis

1 reference

12 December 2020

The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism

1 reference

12 December 2020

JCV detection in multiple sclerosis patients treated with natalizumab

1 reference

12 December 2020

The ups and downs of multiple sclerosis therapeutics

1 reference

12 December 2020

The use of antibodies against the IL-2 receptor in transplantation

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

1 reference

12 December 2020

Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody

1 reference

12 December 2020

Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20

1 reference

12 December 2020

Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial

1 reference

12 December 2020

Primary lymphoma of CNS, mycophenolate mofetil and lupus

1 reference

12 December 2020

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

1 reference

12 December 2020

IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)

1 reference

12 December 2020

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia

1 reference

12 December 2020

Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment

1 reference

12 December 2020

B cell depletion therapy for new-onset opsoclonus-myoclonus

1 reference

12 December 2020

Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus

1 reference

12 December 2020

A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation

1 reference

12 December 2020

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

1 reference

12 December 2020

More on melanoma with transdifferentiation

1 reference

12 December 2020

Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus

1 reference

12 December 2020

A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis

1 reference

12 December 2020

Immunologic and clinical responses to rituximab in a child with opsoclonus-myoclonus syndrome

1 reference

12 December 2020

The PROMiSe trial: baseline data review and progress report.

1 reference

12 December 2020

Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC

1 reference

12 December 2020

TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS

1 reference

12 December 2020

Analysis of cis-acting elements present in the CD20/B1 antigen promoter

1 reference

12 December 2020

Overview of European pilot study of interferon beta-Ib in primary progressive multiple sclerosis.

1 reference

12 December 2020

10.2165/11596920-000000000-00000

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22171583%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

18 January 2020

1049165604

0 references

Fatcat ID

release_h7w7evqusjdahk4a4gp7pu6pwu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/h7w7evqusjdahk4a4gp7pu6pwu

24 November 2022

mapped directly with Wikidata item

1 reference